KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Assets (2020 - 2025)

AbCellera Biologics' Current Assets history spans 6 years, with the latest figure at $695.1 million for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 6.43% year-over-year to $695.1 million, compared with a TTM value of $695.1 million through Sep 2025, down 6.43%, and an annual FY2024 reading of $751.4 million, down 13.83% over the prior year.
  • Current Assets for Q3 2025 was $695.1 million at AbCellera Biologics, down from $742.1 million in the prior quarter.
  • The five-year high for Current Assets was $1.2 billion in Q1 2022, with the low at $695.1 million in Q3 2025.
  • Average Current Assets over 5 years is $886.3 million, with a median of $872.0 million recorded in 2023.
  • Year-over-year, Current Assets surged 32.4% in 2022 and then dropped 19.9% in 2023.
  • Tracing ABCL's Current Assets over 5 years: stood at $929.8 million in 2021, then increased by 10.29% to $1.0 billion in 2022, then fell by 14.97% to $872.0 million in 2023, then decreased by 13.83% to $751.4 million in 2024, then dropped by 7.48% to $695.1 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Current Assets are $695.1 million (Q3 2025), $742.1 million (Q2 2025), and $765.0 million (Q1 2025).